Sirnaomics Ltd. (HKG:2257)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
6.74
+0.27 (4.17%)
At close: Mar 10, 2026
121.71%
Market Cap 733.98M
Revenue (ttm) 7.45M
Net Income (ttm) -110.02M
Shares Out 108.90M
EPS (ttm) -1.27
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 191,450
Average Volume 173,395
Open 6.59
Previous Close 6.47
Day's Range 6.53 - 6.76
52-Week Range 2.83 - 22.78
Beta -0.24
RSI 43.96
Earnings Date Mar 27, 2026

About Sirnaomics

Sirnaomics Ltd., an RNA therapeutics biopharmaceutical company, discovers and develops drugs for indications with medical needs. The company’s therapeutics products focus on oncology and fibrosis, anticoagulant therapies, cardiometabolic disease, complement-mediated diseases, medical aesthetics, and viral infections. Its lead drug candidates include STP705 for the treatment of non-melanoma skin cancer and for focal fat reduction; and STP707 to treat solid tumors. The company is also developing STP122G for the treatment of coagulation disorders;... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2007
Employees 52
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2257
Full Company Profile

Financial Performance

Financial numbers in USD Financial Statements

News

Basal Cell Neoplasms Clinical Trial Pipeline Accelerates as 22+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

New York, USA, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Basal Cell Neoplasms Clinical Trial Pipeline Accelerates as 22+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight Basal Cell N...

6 months ago - Benzinga